首頁 > 市場調查報告書 > 製藥

骨疾病

市場調查報告書

商品編碼

1708232

膝骨關節炎藥物市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

Knee Osteoarthritis Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

出版日期: 2025年03月28日 | 出版商:

Global Market Insights Inc. | 英文 130 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2024 年全球膝關節骨性關節炎藥物市場規模達 67 億美元，預計 2025 年至 2034 年的複合年成長率為 8%。這一成長主要是由於人口老化、久坐不動的生活方式和肥胖率上升導致膝關節骨性關節炎盛行率上升，這些因素增加了對有效治療的需求。市場也受益於人們對早期診斷和治療的認知不斷提高，這鼓勵了及時的醫療干預。此外，藥物配方的進步，包括聯合療法和緩釋選項，正在改善治療效果並促進市場成長。透明質酸 (HA) 黏彈性材料在骨科和運動醫學中的使用率更高，進一步促進了市場積極的發展軌跡。

膝關節骨關節炎藥物主要用於控制患者的疼痛、發炎和病情進展。這些藥物選擇包括非類固醇抗發炎藥、皮質類固醇、黏液補充劑、鎮痛藥和其他旨在緩解症狀和延緩手術干預所需的藥物類型。其中，非類固醇抗發炎藥的收入最高，2024 年將達到 24 億美元，預計到 2034 年將成長到 50 億美元，複合年成長率為 7.7%。非類固醇抗發炎藥物因其廣泛用於治療疼痛和發炎的一線治療而繼續佔據市場主導地位。布洛芬、萘普生和塞來昔布等藥物由於其功效、可用性和成本效益仍然是受歡迎的選擇。局部用藥和 COX-2 選擇性抑制劑等更安全、更有效的製劑的進步進一步促進了該領域的成長。

市場範圍
起始年份	2024
預測年份	2025-2034
起始值	67億美元
預測值	143億美元
複合年成長率	8%

依給藥途徑分類，2024 年，腸外給藥佔最大佔有率，為 51.3%，這是因為與口服和外用藥物相比，腸外給藥具有起效快、生物利用度更高、緩解疼痛時間更長等特徵。腸外給藥包括注射皮質類固醇、黏彈性補充劑（HA注射）和各種生物製劑，通常用於口服治療不足的中度至重度OA病例。人們對微創技術和長效注射劑的日益青睞也推動了該領域的成長。再生療法的進一步發展，包括緩釋製劑、富血小板血漿 (PRP) 和幹細胞療法，預計將促進該領域的成長。

市場按年齡細分為 18-44 歲、45-64 歲和 65 歲以上，其中 65 歲以上年齡層預計將保持突出地位，成長率為 7.6%，到 2034 年將達到 60 億美元。老化會降低關節靈活性、增加發炎並導致軟骨退化，從而導致 OA 盛行率上升。因此，預期壽命的增加、對治療方案認知的提高以及醫療保健支出的增加正在推動這一人群對膝關節骨關節炎藥物的需求。此外，對長效和微創解決方案的偏好繼續增強整個市場的需求。

2024年，美國繼續保持北美膝關節骨關節炎藥物市場的領先地位，估值從2023年的24億美元成長至26億美元。膝關節骨關節炎的高盛行率、人口老化以及對微創治療的日益偏好刺激了對先進療法的需求，為市場擴張做出了重要貢獻。

產業生態系統分析
產業衝擊力
- 成長動力
  - 膝骨關節炎盛行率上升
  - 非手術治療的偏好日益成長
  - 藥物配方的進步
  - 提高認知和早期診斷
- 產業陷阱與挑戰
  - 治療費用高
  - 嚴格的法規核准
成長潛力分析
監管格局
管道分析
未來市場趨勢
波特的分析
PESTEL分析

第4章：競爭格局

介紹
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
策略儀表板

第5章：市場估計與預測：按藥物類型，2021 - 2034 年

主要趨勢
非類固醇抗發炎藥（NSAID）
皮質類固醇
黏液補充療法
- 單次注射
- 3次注射
- 5次注射
止痛藥
其他藥物類型

第6章：市場估計與預測：按管理路線，2021 - 2034 年

主要趨勢
口服
腸外
外用

第7章：市場估計與預測：按年齡層，2021 - 2034 年

主要趨勢
18 - 44
45 - 64
65歲以上

第8章：市場估計與預測：按地區，2021 - 2034 年

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國

第9章：公司簡介

Anika Therapeutics
Avanos
Biotech Healthcare
Bioventus
Ferring Pharmaceuticals
Fidia Pharma
GlaxoSmithKline (GSK)
Haleon
Kenvue
Organon LLC
Pacira Pharmaceuticals
Pfizer
Premier Surgical
Sanofi
Stellar Pharmaceuticals

簡介目錄

Product Code: 13369

The Global Knee Osteoarthritis Drugs Market reached USD 6.7 billion in 2024 and is expected to grow at a CAGR of 8% from 2025 to 2034. This growth is primarily driven by the rising prevalence of knee OA due to an aging population, sedentary lifestyles, and increasing obesity rates, which have amplified the need for effective treatments. The market is also benefiting from growing awareness about early diagnosis and treatment, which encourages timely medical intervention. Additionally, advancements in drug formulations, including combination therapies and extended-release options, are enhancing treatment outcomes and boosting market growth. Higher usage of hyaluronic acid (HA) viscoelastic in orthopedics and sports medicine is further contributing to the market's positive trajectory.

Knee OA drugs primarily manage pain, inflammation, and disease progression in affected patients. These pharmaceutical options include NSAIDs, corticosteroids, viscosupplementation, analgesics, and other drug types aimed at alleviating symptoms and delaying the need for surgical interventions. Among these, NSAIDs generated the highest revenue, reaching USD 2.4 billion in 2024 and projected to grow to USD 5 billion by 2034, with a CAGR of 7.7%. NSAIDs continue to dominate the market due to their widespread use as a first-line treatment for pain and inflammation. Medications such as ibuprofen, naproxen, and celecoxib remain popular choices due to their efficacy, availability, and cost-effectiveness. The segment growth is further reinforced by advancements in safer and more effective formulations, such as topical options and COX-2 selective inhibitors.

Market Scope
Start Year	2024
Forecast Year	2025-2034
Start Value	$6.7 Billion
Forecast Value	$14.3 Billion
CAGR	8%

By route of administration, the parenteral segment held the largest share of 51.3% in 2024, owing to its rapid onset of action, higher bioavailability, and extended duration of pain relief compared to oral and topical options. Parenteral administration includes injectable corticosteroids, viscosupplementation (HA injections), and various biologics, which are commonly used for moderate to severe OA cases where oral treatments prove inadequate. The segment growth is also driven by an increasing preference for minimally invasive techniques and long-acting injectables. Further advancements in regenerative therapies, including sustained-release formulations, platelet-rich plasma (PRP), and stem cell therapies, are expected to boost segment growth.

The market is segmented by age group into 18-44, 45-64, and above 65, with the above 65 segment projected to maintain a prominent position, growing at a rate of 7.6% and reaching USD 6 billion by 2034. Aging reduces joint flexibility, increases inflammation, and leads to cartilage degeneration, which contributes to the rising prevalence of OA. As a result, increased life expectancy, rising awareness about treatment options, and higher healthcare spending are fueling the demand for knee OA drugs within this demographic. Additionally, the preference for long-acting and minimally invasive solutions continues to strengthen demand across the market.

In 2024, the U.S. maintained a leading position in the North American knee OA drugs market, with a valuation of USD 2.6 billion, up from USD 2.4 billion in 2023. The high prevalence of knee OA, an aging population, and a growing preference for minimally invasive treatments have fueled the demand for advanced therapies, contributing significantly to market expansion.

Chapter 1 Methodology and Scope

1.1 Market scope and definition
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising prevalence of knee OA
  - 3.2.1.2 Growing preference for non-surgical treatments
  - 3.2.1.3 Advancements in drug formulations
  - 3.2.1.4 Rising awareness and early diagnosis
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High treatment cost
  - 3.2.2.2 Stringent regulatory approvals
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Future market trends
3.7 Porter's analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2034 ($ Mn)

5.1 Key trends
5.2 Non-steroidal anti-inflammatory drugs (NSAIDs)
5.3 Corticosteroids
5.4 Viscosupplementation
- 5.4.1 Single injection
- 5.4.2 3 injections
- 5.4.3 5 injections
5.5 Analgesics
5.6 Other drug types

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)

6.1 Key trends
6.2 Oral
6.3 Parenteral
6.4 Topical

Chapter 7 Market Estimates and Forecast, By Age Group, 2021 - 2034 ($ Mn)

7.1 Key trends
7.2 18 - 44
7.3 45 - 64
7.4 Above 65

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 India
- 8.4.3 Japan
- 8.4.4 Australia
- 8.4.5 South Korea
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE